Xu-Monette, Z. Y., Luo, C., Yu, L., Li, Y., Bhagat, G., Tzankov, A., Visco, C., Fan, X., Dybkaer, K., Sakhdari, A., Wang, N. T., Yuan, A. F., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Perry, A. M., Song, W., O’Malley, D., … Young, K. H. (2024). DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2024.2384667

Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027

Dioun, S., Chen, L., Melamed, A., Gockley, A., St. Clair, C. M., Hou, J. Y., Khoury‐Collado, F., Hur, C., Elkin, E., Accordino, M., Hershman, D. L., & Wright, J. D. (2022). Dostarlimab for recurrent mismatch repair‐deficient endometrial cancer: A cost‐effectiveness study. BJOG: An International Journal of Obstetrics & Gynaecology, 130(2), 214–221. Portico. https://doi.org/10.1111/1471-0528.17338